# Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Study · id `cardio:ct-nct04289285` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04289285](<https://clinicaltrials.gov/study/NCT04289285>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04289285

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 804 participants.

## Technical summary

Registry record NCT04289285. Randomized; quadruple masking; primary purpose treatment. Start 2020-04-29 (actual); primary completion 2022-02-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 804 participants (enrolled count; ClinicalTrials.gov record NCT04289285, source copy `cardio:ctgov-nct04289285-2022-04-11`, retrieved 2026-10-31)
- Started: 2020-04-29 (actual) (ClinicalTrials.gov record NCT04289285, source copy `cardio:ctgov-nct04289285-2022-04-11`, retrieved 2026-10-31)
- Primary completion: 2022-02-09 (actual) (ClinicalTrials.gov record NCT04289285, source copy `cardio:ctgov-nct04289285-2022-04-11`, retrieved 2026-10-31)
- Completion: 2022-02-09 (actual) (ClinicalTrials.gov record NCT04289285, source copy `cardio:ctgov-nct04289285-2022-04-11`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04289285, source copy `cardio:ctgov-nct04289285-2022-04-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04289285-2022-04-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
- Condition: Hypercholesterolemia
- Intervention (Drug): IBI306 450mg SC Q4W
- Intervention (Drug): Placebo SC Q4W
- Intervention (Drug): IBI306 600mg SC Q6W
- Intervention (Other): Placebo SC Q6W
- Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Innovent Biologics (Suzhou) Co. Ltd. (`cardio:org-innovent-biologics-suzhou-co-ltd`)

## Provenance

Content hash: 2326643068d935775af9a64ed570adb15ed4b444bc5f7bfb8304b3556acc4b49
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
